Mohamed Zaki, Chief Medical Officer at ADC Therapeutics SA. Biography, career history and compensation sourced from SEC proxy filings.
About
Mohamed Zaki, M.D., Ph.D., has served as ADC Therapeutics' Chief Medical Officer since January 2023. From September 2018 to December 2022 he served in senior clinical development roles at AbbVie, including Vice President & Global Head of Oncology Clinical Development and Vice President & Global Head of Hematology Clinical Development, and from 2010 to 2018 in various senior clinical development roles at Celgene; earlier he worked at Sanofi-Aventis and at Centocor, a subsidiary of Johnson & Johnson. Dr. Zaki holds an M.D. and M.S. from Ain Shams University School of Medicine and a Ph.D. held jointly from the University of Pennsylvania and Ain Shams University.
Roles
ADC Therapeutics SA
Chief Medical Officer · Current role
January 2023–present
ADC Therapeutics
Chief Medical Officer
January 2023 - present
AbbVie
Vice President & Global Head of Oncology Clinical Development / Hematology Clinical Development
September 2018 - December 2022
Celgene
Various senior clinical development roles
February 2010 - September 2018
Sanofi-Aventis
Clinical development
—
Centocor (Johnson & Johnson)
Clinical development
—
Fixed Compensation
FY 2025
Salary
$690,121
ComponentAnnual base salary earned in fiscal 2025
All other compensation
$23,820
ComponentHealth, life and disability insurance, 401(k) matching contributions and other wellness benefits
Total compensation
$1,515,566
Performance Compensation
Data from FY 2025
Cash incentive
Non-equity incentive plan compensation
$431,325
Target Opportunity
—
PlanAnnual cash incentive under the ADC Therapeutics Annual Bonus Plan
Stock awards
Stock awards
$370,300
FormRestricted stock units (RSUs), ASC 718 grant-date fair value